Achillion Pharmaceuticals (ACHN) Receives Daily Media Sentiment Score of 0.22

Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.9209238352912 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NASDAQ:ACHN traded up $0.08 on Thursday, reaching $3.68. The stock had a trading volume of 286,094 shares, compared to its average volume of 2,042,168. The firm has a market cap of $490.90, a PE ratio of -5.92 and a beta of 0.89. Achillion Pharmaceuticals has a 1-year low of $2.58 and a 1-year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the business posted ($0.03) EPS. analysts expect that Achillion Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.



ACHN has been the topic of several recent research reports. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, B. Riley initiated coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 target price on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.89.

TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals (ACHN) Receives Daily Media Sentiment Score of 0.22” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/12/achillion-pharmaceuticals-achn-receives-daily-media-sentiment-score-of-0-22.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Insider Buying and Selling by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply